Literature DB >> 22086206

Biological aspects of angiogenesis in multiple myeloma.

Eléonore Otjacques1, Marilène Binsfeld, Agnes Noel, Yves Beguin, Didier Cataldo, Jo Caers.   

Abstract

Multiple myeloma (MM) is a hematological malignancy characterized by the aberrant expansion of malignant plasma cells within the bone marrow (BM). One of the hallmarks of this disease is the close interaction between myeloma cells and neighboring cells within the BM. Angiogenesis, through the activation of endothelial cells, plays an essential role in MM biology. In the current review, we describe the angiogenesis process in MM by identifying the interacting cells, the pro- and anti-angiogenic cytokines modulated, and the extracellular matrix degrading proteases liable to participate in the pathophysiology. Finally, we highlight the impact of hypoxia (through hypoxia-inducible factor-1) and constitutive activation of nuclear factor-κB in this tumor-induced neo-vascularization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22086206     DOI: 10.1007/s12185-011-0963-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  116 in total

1.  Circulating endothelial precursors: mystery, reality, and promise.

Authors:  S Rafii
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.

Authors:  S Colla; P Storti; G Donofrio; K Todoerti; M Bolzoni; M Lazzaretti; M Abeltino; L Ippolito; A Neri; D Ribatti; V Rizzoli; E Martella; N Giuliani
Journal:  Leukemia       Date:  2010-09-02       Impact factor: 11.528

3.  ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin.

Authors:  Abdullah Karadag; Min Zhou; Peter I Croucher
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

4.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

5.  Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.

Authors:  M G Alexandrakis; F H Passam; A Sfiridaki; E Kandidaki; P Roussou; D S Kyriakou
Journal:  Am J Hematol       Date:  2003-04       Impact factor: 10.047

6.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

Authors:  B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

7.  A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.

Authors:  Angelo Vacca; Roberto Ria; Domenico Ribatti; Fabrizio Semeraro; Valentin Djonov; Francesco Di Raimondo; Franco Dammacco
Journal:  Haematologica       Date:  2003-02       Impact factor: 9.941

8.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors:  Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

9.  In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2.

Authors:  D Ribatti; D Leali; A Vacca; R Giuliani; A Gualandris; L Roncali; M L Nolli; M Presta
Journal:  J Cell Sci       Date:  1999-12       Impact factor: 5.285

10.  Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

Authors:  Dirk Hose; Thierry Rème; Tobias Meissner; Jérôme Moreaux; Anja Seckinger; Joe Lewis; Vladimir Benes; Axel Benner; Michael Hundemer; Thomas Hielscher; John D Shaughnessy; Bart Barlogie; Kai Neben; Alwin Krämer; Jens Hillengass; Uta Bertsch; Anna Jauch; John De Vos; Jean-François Rossi; Thomas Möhler; Jonathon Blake; Jürgen Zimmermann; Bernard Klein; Hartmut Goldschmidt
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

View more
  15 in total

Review 1.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

2.  A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression.

Authors:  Sabino Ciavarella; Anna Caselli; Antonella Valentina Tamma; Annalisa Savonarola; Giuseppe Loverro; Roberto Paganelli; Marco Tucci; Franco Silvestris
Journal:  Stem Cells Dev       Date:  2015-03-11       Impact factor: 3.272

3.  Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells.

Authors:  M Koldehoff; D W Beelen; A H Elmaagacli
Journal:  Cancer Gene Ther       Date:  2014-06-06       Impact factor: 5.987

4.  Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma.

Authors:  Michael G Alexandrakis; Ioannis K Neonakis; Constantina A Pappa; Ioannis Konsolas; Maria Kokonozaki; Rodanthi Vyzoukaki; Stella Soundoulounaki; Athina Xekalou; Katerina Sfiridaki; George Tsirakis
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-13       Impact factor: 4.553

5.  Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.

Authors:  Tomohiro Umezu; Hiroko Tadokoro; Kenko Azuma; Seiichiro Yoshizawa; Kazuma Ohyashiki; Junko H Ohyashiki
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

6.  The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.

Authors:  George Tsirakis; Constantina A Pappa; Maria Kaparou; Anna Boula; Vaitsa Katsomitrou; Athina Xekalou; Stavroula Kyriakaki; Michael G Alexandrakis
Journal:  Tumour Biol       Date:  2012-12-16

7.  Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma.

Authors:  George Tsirakis; Parascevi Roussou; Constantina A Pappa; Anna Kolovou; Chrysoula Vasilokonstantaki; Ioannis Miminas; Stavroula Kyriakaki; Athanasios Alegakis; Michael G Alexandrakis
Journal:  Med Oncol       Date:  2013-11-26       Impact factor: 3.064

8.  Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.

Authors:  Marilène Binsfeld; Joséphine Muller; Virginie Lamour; Kim De Veirman; Hendrik De Raeve; Akeila Bellahcène; Els Van Valckenborgh; Frédéric Baron; Yves Beguin; Jo Caers; Roy Heusschen
Journal:  Oncotarget       Date:  2016-06-21

9.  Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors.

Authors:  Eléonore Otjacques; Marilène Binsfeld; Natacha Rocks; Silvia Blacher; Karin Vanderkerken; Agnès Noel; Yves Beguin; Didier Cataldo; Jo Caers
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

10.  Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation.

Authors:  Shuang Wu; Wenjun Yu; Xiaoyan Qu; Rong Wang; Ji Xu; Qiguo Zhang; Jiaren Xu; Jianyong Li; Lijuan Chen
Journal:  J Hematol Oncol       Date:  2014-05-07       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.